Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$146.48 USD
+0.79 (0.54%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $146.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
JNJ 146.48 +0.79(0.54%)
Will JNJ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Other News for JNJ
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
J&J reports positive phase 3 data for nipocalimab for neuromuscular disease
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Johnson & Johnson: Nipocalimab meets primary endpoint in Phase 3 trial
J&J: Nipocalimab Phase 3 trial demonstrates sustained disease control